Patent application number | Description | Published |
20090111123 | COMPOSITIONS FOR DETECTING ANTIBODIES TO BABESIA MICROTI AND METHODS OF USES THEREOF - The present invention relates to one or more peptides which may be used to test for the presence of antibodies to | 04-30-2009 |
20090123946 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 05-14-2009 |
20090124022 | ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies. | 05-14-2009 |
20090232797 | PLASMODIUM MALARIAE AND PLASMODIUM OVALE GENES AND USES THEREOF - The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the | 09-17-2009 |
20090263894 | ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies. | 10-22-2009 |
20090269777 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 10-29-2009 |
20100227775 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 09-09-2010 |
20100247576 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 09-30-2010 |
20110311572 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 12-22-2011 |
20130330359 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS - Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders. | 12-12-2013 |